Clinical Trial: Trial of Mesalamine for the Treatment of Active Microscopic Colitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis.
Brief Summary: Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Subjects that show improvement will be followed for 4 weeks post medication.
Detailed Summary:
We propose a prospective, randomized trial of mesalamine at 1.2g and 4.8g doses for the treatment of microscopic colitis. Our hypothesis is mesalamine is safe and effective for the treatment of diarrhea in microscopic colitis and that the 4.8g dose is more effective than the 1.2g dose.
We will recruit 70 subjects. The subjects will be randomized into to two groups, 4.8g dose, and 1.2g dose groups. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Responders will be followed for 4 weeks post medication.
Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Subjects will be excluded if they have unsuccessful treatment or side effects to 5-ASA drugs, oral corticosteroids, or salicylate. and antibiotics, mesalamine, bismuth or steroid use in the last two weeks. Subjects may not be on anticholinergics, cholestyramine, digoxin. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions.
A two-sample z-score test for proportions will be used to test whether relief rates are different between groups.
Sponsor: Mayo Clinic
Current Primary Outcome: To determine the efficacy of mesalamine at 1.2g and 4.8g doses in microscopic colitis for providing relief of diarrhea
Original Primary Outcome: Same as current
Current Secondary Outcome: To compare the safety and tolerability of mesalamine at 1.2g and 4.8g doses in patients with microscopic colitis.
Original Secondary Outcome: Same as current
Information By: Mayo Clinic
Dates:
Date Received: August 4, 2009
Date Started: February 2007
Date Completion:
Last Updated: May 20, 2011
Last Verified: May 2011
